Literature DB >> 24703097

Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system.

Masami Tanaka1, Keiko Tanaka2.   

Abstract

The myelin oligodendrocyte glycoprotein (MOG) is considered as a candidate marker of demyelinating disorders of the central nervous system. Here, sera samples from 48 consecutive Japanese patients with myelitis or optic neuritis (ON), but negative for anti-aquaporin (AQP) 4 antibodies (Abs), and 14 anti-AQP4 Ab-positive patients were tested for anti-MOG Abs using a cell-based immunofluorescence assay with full-length human MOG cDNA. Anti-MOG Abs were detected in four male patients with myelitis or ON. Oveall, 13 neuromyelitis optica-seronegative and all anti-AQP4 Ab-positive patients were negative for anti-MOG Abs. Hence, these findings warrant further examinations in large cohort series.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti- myelin oligodendrocyte glycoprotein antibodies; Anti-aquaporin 4 antibodies; Cell-based immunofluorescence assay; Multiple sclerosis; Neuromyelitis optica; Optic neuritis

Mesh:

Substances:

Year:  2014        PMID: 24703097     DOI: 10.1016/j.jneuroim.2014.03.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

Review 3.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

4.  Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis.

Authors:  Ryusaku Matsuda; Takeshi Kezuka; Akihiko Umazume; Yoko Okunuki; Hiroshi Goto; Keiko Tanaka
Journal:  Neuroophthalmology       Date:  2015-08-25

5.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

Review 6.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

7.  Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.

Authors:  Hideki Nakajima; Masakatsu Motomura; Keiko Tanaka; Azusa Fujikawa; Ruka Nakata; Yasuhiro Maeda; Tomoaki Shima; Akihiro Mukaino; Shunsuke Yoshimura; Teiichiro Miyazaki; Hirokazu Shiraishi; Atsushi Kawakami; Akira Tsujino
Journal:  BMJ Open       Date:  2015-04-02       Impact factor: 2.692

8.  Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.

Authors:  Yaping Yan; Yujing Li; Ying Fu; Li Yang; Lei Su; Kaibin Shi; Minshu Li; Qiang Liu; Aimee Borazanci; Yaou Liu; Yong He; Jeffrey L Bennett; Timothy L Vollmer; Fu-Dong Shi
Journal:  Sci China Life Sci       Date:  2016-02-26       Impact factor: 6.038

Review 9.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

10.  Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.

Authors:  Melania Spadaro; Lisa Ann Gerdes; Markus Krumbholz; Birgit Ertl-Wagner; Franziska Sabrina Thaler; Elisabeth Schuh; Imke Metz; Astrid Blaschek; Andrea Dick; Wolfgang Brück; Reinhard Hohlfeld; Edgar Meinl; Tania Kümpfel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.